The Cochrane editors statement is shown below.However, there is no description why the topic has low priority. We found strong evidence that in RCTs published so far, vitamin C has prevented atrial fibrillation outside of the USA. Thus, was the low priority caused by effects seen only outside of the USA or because vitamin C is not interesting in the view of the Cochrane editors. The manuscript for the Cochrane review is available at: http://www.mv.helsinki.fi/home/hemila/H/HH_2015_CochAF_Protocol.pdf. The review was not rejected because of valid scientific reasons, see responses to reviewer comments at: http://www.mv.helsinki.fi/home/hemila/H/VitC_AF_1308_reviewer_comments.pdf. A shortened version was published in BMC Cardiovascular Disorders: https://doi.org/10.1186/s12872-017-0478-5. ## Reason for withdrawal from publication: The CRG withdrew this protocol as the current author team is unable to progress to the final stage of the review. The editors consider this title as low priority for the current portfolio of the Heart Group and therefore this title is not open to a new author team.
Fields of Science
- 3142 Public health care science, environmental and occupational health
Hemilä, H., & Suonsyrjä, T. (2016). Vitamin C for treating atrial fibrillation: [Withdrawal from publication]. Cochrane database of systematic reviews, (6), [CD011471]. https://doi.org/10.1002/14651858.cd011471.pub2